These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 21216929)

  • 1. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
    Janku F; Tsimberidou AM; Garrido-Laguna I; Wang X; Luthra R; Hong DS; Naing A; Falchook GS; Moroney JW; Piha-Paul SA; Wheler JJ; Moulder SL; Fu S; Kurzrock R
    Mol Cancer Ther; 2011 Mar; 10(3):558-65. PubMed ID: 21216929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA mutations in advanced cancers: characteristics and outcomes.
    Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
    Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.
    Janku F; Lee JJ; Tsimberidou AM; Hong DS; Naing A; Falchook GS; Fu S; Luthra R; Garrido-Laguna I; Kurzrock R
    PLoS One; 2011; 6(7):e22769. PubMed ID: 21829508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
    Janku F; Wheler JJ; Naing A; Falchook GS; Hong DS; Stepanek VM; Fu S; Piha-Paul SA; Lee JJ; Luthra R; Tsimberidou AM; Kurzrock R
    Cancer Res; 2013 Jan; 73(1):276-84. PubMed ID: 23066039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
    Garrido-Laguna I; Hong DS; Janku F; Nguyen LM; Falchook GS; Fu S; Wheler JJ; Luthra R; Naing A; Wang X; Kurzrock R
    PLoS One; 2012; 7(5):e38033. PubMed ID: 22675430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
    Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
    BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia.
    Yip WK; Choo CW; Leong VC; Leong PP; Jabar MF; Seow HF
    APMIS; 2013 Oct; 121(10):954-66. PubMed ID: 23992303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001.
    Mohseni M; Park BH
    J Clin Invest; 2010 Aug; 120(8):2655-8. PubMed ID: 20664174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.
    Dienstmann R; Serpico D; Rodon J; Saura C; Macarulla T; Elez E; Alsina M; Capdevila J; Perez-Garcia J; Sánchez-Ollé G; Aura C; Prudkin L; Landolfi S; Hernández-Losa J; Vivancos A; Tabernero J
    Mol Cancer Ther; 2012 Sep; 11(9):2062-71. PubMed ID: 22723336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
    Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
    Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population.
    Hsieh LL; Er TK; Chen CC; Hsieh JS; Chang JG; Liu TC
    Clin Chim Acta; 2012 Oct; 413(19-20):1605-11. PubMed ID: 22579930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
    Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
    Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas.
    Schönleben F; Qiu W; Allendorf JD; Chabot JA; Remotti HE; Su GH
    J Gastrointest Surg; 2009 Aug; 13(8):1510-6. PubMed ID: 19440799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.